BioXcel Therapeutics, Inc.
BTAI
$1.17
-$0.02-1.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 161.22% | -18.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 161.22% | -18.33% | |||
| Cost of Revenue | 190.91% | -89.72% | |||
| Gross Profit | 157.47% | 569.23% | |||
| SG&A Expenses | -29.29% | -4.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.43% | -11.52% | |||
| Operating Income | 26.74% | 11.47% | |||
| Income Before Tax | 59.42% | -61.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 59.42% | -61.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.42% | -61.10% | |||
| EBIT | 26.74% | 11.47% | |||
| EBITDA | 26.87% | 11.52% | |||
| EPS Basic | 73.64% | 11.00% | |||
| Normalized Basic EPS | 73.48% | 11.55% | |||
| EPS Diluted | 73.64% | 11.00% | |||
| Normalized Diluted EPS | 73.48% | 11.55% | |||
| Average Basic Shares Outstanding | 53.96% | 81.00% | |||
| Average Diluted Shares Outstanding | 53.96% | 81.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||